Tharimmune raises executive salaries and adjusts change of control terms

Tharimmune, Inc. (NASDAQ:THAR), a micro-cap biotech company with a market capitalization of $17 million, announced Monday that its Compensation Committee approved changes to the compensation arrangements for its Chief Executive Officer, Sireesh Appajosyula, and Executive Chairman, Vincent LoPriore. The company’s stock has shown significant volatility, with InvestingPro data showing a 142% surge over the past six months despite recent pullbacks.

According to a statement based on a recent SEC filing, the Committee approved an increase of $100,000 to the base salary of both Mr. Appajosyula and Mr. LoPriore, setting their new annual salaries at $385,000.

The Committee also amended the terms of potential payments in the event of a change of control. If either executive’s employment is terminated within twelve months following a change of control of the company, the payment will increase from two times to three times their base salary and target bonus.

These changes were approved on September 2 by the Compensation Committee of Tharimmune’s Board of Directors. The company is incorporated in Delaware and is listed on the Nasdaq Stock Market under the ticker THAR.

The information is based on a press release statement contained in the company’s SEC filing.

In other recent news, Tharimmune, Inc. reported that its stockholders’ equity now surpasses the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. This development follows two registered direct offerings and a private placement, raising approximately $7.05 million in gross proceeds. Tharimmune also announced a $5.35 million direct offering of its common stock, issuing 1,188,888 shares at $4.50 per share under a shelf registration statement. Furthermore, the company regained compliance with Nasdaq Listing Rule 5550(b)(1), confirming stockholders’ equity of $6,876,335 as of August 31, 2025. On the product front, Tharimmune revealed positive results from a pharmacokinetic simulation analysis of its TH104 buccal film, which may offer protection against opioid-induced respiratory depression for up to 24 hours. Additionally, Tharimmune expanded its intellectual property portfolio for its TH-104 transmucosal film technology, securing patents in Japan, Mexico, Australia, and the United States. These patents extend protection for the opioid countermeasure technology until at least 2040.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.